Studies have demonstrated that ICIs have better efficacy in NSCLC (with or without BM) patients whose PD-L1 expression is ≥1% [59,65,73], while responses can still occur in those with PD-L1 expression <1% or PD-L1-negative tumors [44,67,73–75]. Here, CD274 is linked to non-small cell lung carcinoma.